- Home
- RMCO vs CUE Comparison
RMCO vs CUE Comparison
Compare RMCO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | CUE |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMCO | CUE |
|---|---|---|
| Price | $3.95 | $0.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 41.3K | ★ 1.8M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,798,352.00 | ★ $7,100,000.00 |
| Revenue This Year | $531.90 | N/A |
| Revenue Next Year | $200.00 | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | N/A |
| 52 Week Low | $0.91 | $0.23 |
| 52 Week High | $4.76 | $1.54 |
Technical Indicators
Market Signals| Indicator | RMCO | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 50.17 |
| Support Level | $3.41 | $0.28 |
| Resistance Level | $4.43 | $0.37 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 63.98 | 55.57 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.